Presentations

Monday 27th

	Monday 27^th March
Banff Pre-meeting: New endpoints for Next Generation Clinical Trials Chairs: Denis Glotz, Peter Nickerson
Welcome and opening Remarks: History and Future of the Banff Classification, Where the Present Lesion Scoring Criteria Came From, and the Continued Need for Ease of Use and Time Efficiency Kim Solez, Alberta, Canada Next Generation Clinical Trials: how the Banff classification needs to support these Kim Solez, Alberta, Canada DSA-monitoring as an end point Anat Tambur, Chicago, USA Refined histology scoring as a reliable endpoint Bob Colvin, Boston, USA The Molecular Microscope as an endpoint Philip Halloran, Alberta, Canada Clinical trials: the FDA unmet needs Mark Stegall, Rochester, USA Potential endpoints for response to treatment of ABMR in heart transplant recipients Luciano Potena, Bologna, Italy
Banff Pre-meeting: New endpoints for Next Generation Clinical Trials Chairs: Denis Glotz, Peter Nickerson
Potential endpoints for response to treatment of ABMR in liver transplant recipients Sandy Feng, San Francisco, USA Potential endpoints for response to treatment of ABMR in kidney transplant recipients Mark Stegall, Rochester, USA Optimizing Statistical methods for generating robust endpoints Dorry Segev, Baltimore, USA Adopting a histo-immuno-clinico-laboratory composite endpoint: The iBox Alexandre Loupy, Paris, France

Tuesday 28th

	Tuesday 28^th March
Up-dates from Banff Working Groups Chairs: Lorrain Racusen, Kim Solez
Report on Banff Foundation Michael Mengel, Alberta, Canada Proposal for new Banff Working Group: Transplantation HIV+ to HIV+ Serena Bagnasco, Baltimore, USA EM scoring BWG Harsharan Singh, Chapel Hill, USA Highly sensitized BWG Carrie Schinstock, Rochester, USA Recurrent GN BWG Nada Alachkar, Baltimore, USA TMA in transplants BWG Marjan Afrouzian, Galveston, USA TCMR/borderline BWG Parmjeet Randhawa, Pittsburg, USA; and Volker Nickeleit, Chapel Hill, USA Molecular BWG Michael Mengel, Alberta, Canada
Banff Concurrent Kidney 1: The significance of i-IFTA revisiting TCNR and mixed rejection Chairs: Ian Gibson, Candice Roufosse What defines chronic-active TCMR Roz Mannon, Alabama, USA Pathology of mixed rejection Ian Gibson, Manitoba, Canada Pathology of the late post-transplant kidney and the role of non T cells Lynn Cornell, Rochester, USA Molecular correlates of chronic TCMR Enver Akalin, New York, USA Do we need different scoring rules in early and late allograft biopsies? Maarten Naesens, Leuven, Belgium i IFTA: significance and prognostic value Clement Gosset, Paris, France Treatment of late and mixed rejection pathology Brian Nankivell, Westmead, Australia
Banff Concurrent: Lung-Antibody-mediated rejection, to be continued Chairs: David Hwang and Elizabeth Pavlisko The multidisciplinary approach to AMR in lung transplantation – reaching a consensus Deborah Levine, San Antonio, USA Histopathology of AMR in the lung – Part 1 Fiorella Calabrese, Padova, Italy Histopathology of AMR in the lung – Part 2 Gerry Berry, Stanford, USA DSAs in lung transplantation Adriana Zeevi, Pittsburg, USA Molecular signals and lung transplantation Phil Halloran, Alberta, Canada Relevant endpoints in lung AMR treatment Antoine Roux, Paris, France Therapeutic options and strategies – the old and the new Ramsey Hachem, Missouri, USA
Banff Concurrent Liver 1 Chairs: Anthony Jake Demetris and Stefan Hübscher Introduction – aims of liver sessions Anthony Jake Demetris, Pittsburg, USA Pathology of Extra-corporeal perfusion of Liver Allografts – what to examine and how does it correlates with outcome Annette Gouw, Groningen, the Netherlands The prospects of extra-corporeal machine perfusion of donor livers Robert Porte, Groningen, the Netherlands Fibrosis and Structural Decline of Liver Allografts: what and how to measure and potential underlying causes Carla Venturi Monteagudo, Brussels, Belgium A Pathologists Guide to Evaluating the Long-Surviving Allograft: important features, stains, and approach to better understanding of chronic AMR Stefan Hübscher, Birmingham, United Kingdom

Wednesday 29th

	Wednesday 29^th March
Banff Plenary 1: The integrated Diagnosis: Histology + DSA Chairs: Phil Halloran, Christophe Legendre
DSA positive and then – To biopsy or not? Peter Nickerson, Manitoba, Canada HLA DSA properties assesment in the real life : what does it add? Adriana Zeevi, Pittsburg, USA The value of DSA in managing ABMR diagnostic, prognostic, and response to therapy Carmen LeFaucher, Paris, France Do we need DSA to diagnose ABMR – the pathologists view? Mark Haas, Sherman Oaks, USA

SCT Plenary 1: State of the art: Cellular repair of damaged organs Chairs: Laura Lladó and Kim Solez
Cell theraphy in lung diseases Anna Serrano Mollar, Barcelona, Spain Cell implantation after myocardial infarction: a 10 years experience from ICREC laboratory Santiago Roura, Barcelona, Spain Repopulating scaffoldings in kidney and liver Mireia Caralt, Barcelona, Spain

Joint Plenary abstracts 1 Chairs: Ramón Charco and Brian Nankivell

SCT Plenary 2: Key issues in clinical trials in solid organ transplantation Chairs: Denis Glotz and Frederic Oppenheimer
The challenge of therapeutic innovation in organ transplantation Josep M. Grinyó, Barcelona, Spain Methodological constraints in the design of clinical trials Daniel Serón, Barcelona, Spain New endpoints for New Generation Clinical Trials: A Summary of Banff proposals Julio Pascual, Barcelona, Spain Clinical trials investment. The industry point of view Guido Junge, Basilea, Switzerland

SCT Oral Session 1: Experimental and Immunology aspects Chairs: Lluís Guirado and Eduard Palou
Banff concurrent: Pancreas Chairs: Cinthia Rachemberg Pancreas perfusion with hypothermic machine: pancreas and duodenal histology up to 24 hours Julien Branchereau, Nantes, France Effect of immunosuppressive therapies on transplanted islets and pancreas Javier Trinanes Ramos, Leiden, the Netherlands Outcome of pancreas transplantation alone with portal venous drainage vs. systemic venous drainage Stephen Bartlett, Baltimore, USA Vascular remodelling following whole pancreas transplantation Steven White, New Castle, United Kingdom Impact of BK infection in pancreas transplant recipients Maria Fernanda Toniolo, Buenos Aires, Argentina Histology of refractory rejection John Papadimitriou, Maryland, USA Comparison between rejection in pancreas and kidney biopsies in SPK patients with graft dysfunction. Pablo Uva, Buenos Aires, Argentina Case presentation Diego Cantarovich, Nantes, France
Banff concurrent: Heart Chairs: Annalisa Angelini, Gerald Berry The contribution of the pathologist to expand the donor pool in cardiac transplantation Ornella Leone, Bologna, Italy The multifaceted pathologies of CAV Gregory Fishbein, Los Angeles, USA Vasculitis process at the base of CAV Marny Fedrigo, Padova, Italy Immunopathology of CAV Manon Huibers, Utrecht, the Netherlands Chronic injury to the microcirculation in EMB Dylan Miller, Salt Lake City, USA; and Patricia Revello, Salt Lake City, USA cfDNA in heart transplantation injury to the microcirculation in EMB Kiran Krush, Stanford, USA Gene expression on FFPE EMB for the diagnosis of rejection in Heart Transplantation Michael Mengel, Alberta, Canada MicroRNA on FFPE EMB for the diagnosis of rejection in Heart Transplantation Annalisa Angelini, Padova, Italy Does chronic ABMR exist in cardiac transplantation? Patrick Bruneval, Paris, France Towards an uniform terminology for the pathology of CAV Gerald Berry, Stanford, USA
Banff concurrent: VCA Chairs: Linda Cendales, Brand Farris Chronic rejection in VCA Jean Kanitakis, Lyon, France VCA skin scoring system in a preclinical model Robert Colvin, Boston, USA The role of immunohistochemistry and additional tools in the diagnosis of VCA skin rejection David Elder, Philadelphia, USA Skin containing VCA as a monitoring tool for intestinal transplantation Annemarie Weissenbacher, Oxford, United Kingdom Uterus transplant rejection: a provisional scoring system for rejection Carl Johan Molne, Göteborg, Sweden

Thursday 30th

	Thursday 30^th March
Banff Symposium: The Molecular Microscope in routine Transplantation Pathology Chairs: Mark Haas and Alex Loupy
Centralized Molecular diagnostics: Methods, platforms, pitfalls. Phil Halloran, Alberta, Canada Decentralized Molecular diagnostics: Pros and Cons. Bob Colvin, Boston, USA
SCT Plenary 3: How to increase donor pool Chairs: Julio Pascual and Teresa Pont
The changing scenario for organ donation Elisabeth Coll, Madrid, Spain Donor quality assessment Francesc Moreso, Barcelona, Spain Omics to asses quality of donated organs Rainer Oberbauer, Vienna, Austria
Banff Plenary 2: Staging and Grading of rejection: the need in the era of Precision Medicine Chairs: Robert Colvin and Philip Halloran
IgA Nephropathy: Morphologic Findings Associated with Disease Progression and Therapeutic Response. A Working Group Approach Mark Haas, Sherman Oaks, USA Grading of microcirculation inflammation in heart allografts Jean-Paul Duong Van Huyen, Paris, France Vascularized Allograft biopsies revisited Linda Cendales, Durham, USA
Joint Plenary abstracts 2 Chairs: Josep Maria Cruzado and Michael Mengel
SCT Plenary 4: Precision medicine in solid organ transplantation Chairs: Fritz Diekmann, Nicolás Manito
Pharmacogenetics to tailor drug exposure and outcomes in kidney transplant Dennis Hesselink, Rotterdam, Holand Monitoring memory B Cells responses in transplantation Oriol Bestard, Barcelona, Spain State of the art: Finger prints of tolerance Maria Hernández, London, United Kingdom Personalized medicine in Liver Transplantation Miquel Navasa, Barcelona, Spain Measuring patients alloreactivity to personalize treatment Merce Brunet, Barcelona, Spain
SCT Oral Session 2: Update in organ donation Chairs: David Paredes and Alberto Sandiumenge

Banff concurrent: Kidney 2 Chairs: Mark Haas, Alex Loupy Final decision on PVN scoring Volker Nickeleit, Chapel Hill, USA EM scoring system – are we ready for adoption into the classification? Candice Roufosse, London, United Kingdom; and Harsharan Singh, Chapel Hill, USA Standardized Banff scoring – A web-based approach Jan Ulrich Becker, Cologne, USA Scoring of i-IFTA: potential rules and role in chronic TCMR Parmjeet Randhawa, Pittsburg, USA
Banff concurrent: Liver 2 Chairs: Chris Bellamy and Sandy Feng Serum DSA in long-surviving liver allograft recipients: an algorithmic approach to determine potential clinical significance Sandy Feng, San Francisco, USA Focusing the “molecular microscopic” on liver allografts: integration of genomics and tissue pathology Alberto Sánchez-Fueyo, London, United Kingdom Subclinical liver allograft rejection and “tolerance-related” liver infiltrates Richard Taubert, Hannover, Germany

Friday 31st

	Friday 31^st March
Banff summary and closing remarks Chair: Kim Solez
Kidney summary Mark Haas, Sherman Oaks, USA Liver summary Anthony Jake Demetris, Pittsburg, USA Pancreas summary Cinthia Drachenberg, Baltimore, USA Heart summary Patric Burneval, Paris, France Lung summary David Hwang, Toronto, Canada Vascularized Composite Allografts summary Linda Cendales, Durham, USA Closing remarks Kim Solez, Alberta, Canada
SCT Plenary 5: The future of DCD in solid organ transplantation Chairs: Marta Crespo and Núria Masnou
DCD Donors in Spain: pearls and pitfalls Elisabeth Coll, Madrid, Spain Risk factors associated with DCD kidney function and survival José Maria Portolés Madrid, Spain Will normothermic perfusion become the new standard for the maintenance of DCD donors? Thoracic normothermic perfusion. Steve Large, Cambridge, United Kingdom Abdominal normothermic perfusion. Constantino Fondevila, Barcelona, Spain Update on the results of recent clinical trials on organ machine perfusion prior to transplantation: Lung. Irene Bello, Barcelona, Spain Liver. Rubén Ciria, Córdoba, Spain Kidney
SCT Oral Session 3:Hot topics in outcomes after solid organ transplantation Chairs: Gonzalo Crespo and Antonio Román